Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis
- 3 May 2002
- Vol. 30 (5) , 75-79
- https://doi.org/10.1016/s8756-3282(02)00715-9
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnoverBone, 1997
- Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosisBone, 1996
- Clinical significance of antibodies against calcitoninExperimental and Clinical Endocrinology & Diabetes, 1995
- A 5‐year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calciumEuropean Journal of Clinical Investigation, 1994
- Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitoninJournal of Bone and Mineral Research, 1994
- Acute effects of nasal salmon calcitonin on calcium and bone metabolismCalcified Tissue International, 1993
- A clinical trial on the effects of a combination of elcatonin (Carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal womenCalcified Tissue International, 1993
- Behandlung der primären Osteoporose mit Calcium und LachscalcitoninDeutsche Medizinische Wochenschrift (1946), 1990
- NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSISClinical Endocrinology, 1989
- Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics.Journal of Clinical Investigation, 1989